Search by Drug Name or NDC
NDC 00574-4024-35 erythromycin 5 mg/g Details
erythromycin 5 mg/g
erythromycin is a OPHTHALMIC OINTMENT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Padagis US LLC. The primary component is ERYTHROMYCIN.
MedlinePlus Drug Summary
Ophthalmic erythromycin is used to treat bacterial infections of the eye. This medication is also used to prevent bacterial infections of the eye in newborn babies. Erythromycin is in a class of medications called macrolide antibiotics. It works by killing bacteria that cause infections.
Related Packages: 00574-4024-35Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Erythromycin Ophthalmic
Product Information
| NDC | 00574-4024 |
|---|---|
| Product ID | 0574-4024_e5de2c54-b0ab-4466-8102-74d7da5ac337 |
| Associated GPIs | 86101025004210 |
| GCN Sequence Number | 007948 |
| GCN Sequence Number Description | erythromycin base OINT. (G) 5 MG/GRAM OPHTHALMIC |
| HIC3 | Q6W |
| HIC3 Description | OPHTHALMIC ANTIBIOTICS |
| GCN | 33540 |
| HICL Sequence Number | 004022 |
| HICL Sequence Number Description | ERYTHROMYCIN BASE |
| Brand/Generic | Generic |
| Proprietary Name | erythromycin |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | erythromycin |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | OINTMENT |
| Route | OPHTHALMIC |
| Active Ingredient Strength | 5 |
| Active Ingredient Units | mg/g |
| Substance Name | ERYTHROMYCIN |
| Labeler Name | Padagis US LLC |
| Pharmaceutical Class | Decreased Sebaceous Gland Activity [PE], Macrolide Antimicrobial [EPC], Macrolide [EPC], Macrolides [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA062447 |
| Listing Certified Through | 2024-12-31 |
Package
Package Images
NDC 00574-4024-35 (00574402435)
| NDC Package Code | 0574-4024-35 |
|---|---|
| Billing NDC | 00574402435 |
| Package | 1 TUBE in 1 CARTON (0574-4024-35) / 3.5 g in 1 TUBE |
| Marketing Start Date | 2014-05-08 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 2.63249 |
| Pricing Unit | GM |
| Effective Date | 2024-02-21 |
| NDC Description | ERYTHROMYCIN 0.5% EYE OINTMENT |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1, 5 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |
Standard Product Labeling (SPL)/Prescribing Information SPL 87b45f99-a4d1-47e0-bbb6-50ca19c10010 Details
DESCRIPTION:
Erythromycin Ophthalmic Ointment belongs to the macrolide group of antibiotics. It is basic and readily forms a salt when combined with an acid. The base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin ((3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-dideoxy-3-C-methyl-3-0-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-ß-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione) is antibiotic produced from a strain of Streptomyces erythraeus. It has the following structural formula:
Each gram contains Erythromycin USP 5 mg in a sterile ophthalmic base of mineral oil and white petrolatum.
CLINICAL PHARMACOLOGY:
Microbiology:
Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitro and in clinical infections:
Streptococcus pyogenes (group A ß-hemolytic)
Alpha-hemolytic streptococci (viridans group)
Staphylococcus aureus, including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin)
Streptococcus pneumonia
Mycoplasma pneumoniae (Eaton Agent, PPLO)
Haemophilus influenzae (not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved)
Treponema pallidum
Corynebacterium diphtheriae
Neisseria gonorrhoeae
Chlamydia trachomatis
INDICATIONS AND USAGE:
For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin.
For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis. The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrheae is not established.
For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.
CONTRAINDICATIONS:
PRECAUTIONS:
General:
The use of antimicrobial agents may be associated with the overgrowth of nonsusceptible organisms including fungi; in such a case, antibiotic administration should be stopped and appropriate measures taken.
Information for Patients:
Avoid contaminating the applicator tip with material from the eye, fingers, or other source.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Two year oral studies conducted in rats with erythromycin did not provide evidence of tumorigenicity. Mutagenicity studies have not been conducted.
No evidence of impaired fertility that appeared related to erythromycin was reported in animal studies.
Pregnancy:
Teratogenic effects -
Pregnancy Category B.
Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. No evidence of harm to the fetus that appeared related to erythromycin was reported in these studies. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed.
ADVERSE REACTIONS:
The most frequently reported adverse reactions are minor ocular irritations, redness, and hypersensitivity reactions.
To report SUSPECTED ADVERSE REACTIONS, contact Perrigo at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DOSAGE AND ADMINISTRATION:
In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of Erythromycin Ophthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.
HOW SUPPLIED
Sterile Erythromycin Ophthalmic Ointment USP, 5 mg/g as follows:
3.5 g (1/8 oz) tamper-evident tubes NDC 0574-4024-35
24 x 3.5 g (1/8 oz) Hospital-Pak (for hospital use only) NDC 0574-4024-39
Carton of fifty (50) Unit Dose 1 g tubes NDC 0574-4024-50
Store at controlled room temperature 15°-30°C (59°-86°F). Avoid excessive heat.
Protect from freezing.
SPL UNCLASSIFIED SECTION
Package/Label Display Panel - Label
Package/Label Display Panel - Carton
Package/Label Display Panel-Hospital - Pak
HOSPITAL-PAK
Rx Only
NDC 0574-4024-39
Erythromycin Ophthalmic Ointment USP
STERILE – 5 mg per Gram
For Use in High Volume Neonatal Care
HOSPITAL USE ONLY
24 x 1/8 OZ (3.5 g)
Each gram contains 5 mg of Erythromycin USP in a sterile ophthalmic base of mineral oil and white petrolatum.
The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - 50 Unit Doses
Rx Only
NDC 0574-4024-50
Erythromycin Ophthalmic Ointment USP, 0.5% (5 mg/g)
DO NOT REUSE. ONCE OPENED, DISCARD
STERILE
50 Unit Doses
Sterile Ophthalmic Ointment weighing 1 gram each.
The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.
INGREDIENTS AND APPEARANCE
| ERYTHROMYCIN
erythromycin ointment |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| Labeler - Padagis US LLC (967694121) |